Health
Uganda, Canada test drug to treat brain disease
Publish Date: May 03, 2013
Uganda, Canada test drug to treat brain disease
Human brain
  • mail
  • img
newvision


Canada is funding testing in Uganda of a popular off-patent antidepressant drug to fight a fungal brain disease that claims more than half a million lives in sub-Saharan Africa every year.


Sertraline, better known as Zoloft or Lustral, was first introduced by pharmaceutical giant Pfizer in 1991. It has since become the second-most prescribed antidepressant in the United States.

But recent lab work at the University of Utah found that the drug also has a potent fungicidal effect, with several women taking it to alleviate symptoms of premenstrual syndrome reporting it also cleared up their yeast infections.

With Canadian backing, researchers at Uganda's Infectious Disease Institute at Makerere University now hope to show that it can be used to stem early deaths from cryptococcal meningitis -- an infection of the tissue covering the brain that claims 600,000 lives in sub-Saharan Africa annually.

"We're hoping to teach an old drug new tricks," lead researcher David Meya told AFP in a telephone interview from Uganda Tuesday.

"Our hope is that if this drug works against cryptococcal meningitis, we can cut mortality rates by 40 to 50 percent, which would be a huge leap."

More than 30 percent of patients die within 10 weeks of onset of the disease, which has been linked to AIDS.

Currently, it is being treated with one of two drugs: flucytosine and amphotericin. Both were developed in the 1950s and are "very expensive and not widely available in sub-Saharan Africa," Meya said.

A third drug, fluconazole, has also been tried but is less effective, he added.

"So if we discover another drug that is more effective against cryptococcal meningitis and is cheaper, we can substantially bring down mortality rates in sub-Saharan Africa."

Developing and testing a new drug from scratch typically takes seven to 10 years. Repurposing a drug already on the market in this case is expected to take only four years, Meya said.

"We already know this drug's safety profile. We just need to do a clinical trial to see how effective varying amounts of the drug are at treating a new disease," he noted.

Furthermore, since drug patents for sertraline are now expired, it would be possible for generic drug makers to produce and sell it more cheaply.

The Canadian government is helping Meya's team with $100,000 (US$99,364) in seed funding through a program called Grand Challenges Canada.

It is one of more than 100 grants to innovators in 13 developing nations and in Canada "to pursue bold, creative ideas for tackling health problems," according to a statement.

The funds -- $10.9 million in total -- are to be spent on trying out remote diagnostics and monitoring, health protection, as well as drug and vaccine development and accessibility.

Other projects include a vaccine for smokers against nicotine's addictive effect; a glucose meter cell phone attachment for diabetics and a cheap instant test strip to diagnose deadly diseases like dengue and Ebola. AFP

 

The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact digital@newvision.co.ug

  • mail
  • img
blog comments powered by Disqus
Also In This Section
UN Ebola head warns against complacency
The head of the UN''s Ebola fighting force warns against complacency as the battle against the disease enters its final lap....
All health workers must be vaccinated against HBV
The ministry of health has launched new rules, making it compulsory for all health workers to be vaccinated against hepatitis B virus (HBV)....
Ebola virus has mutated less than scientists feared
The Ebola virus is not mutating as quickly as scientists had feared, which is good news for treating the disease and preventing its spread....
Korea pledges sh25b to reduce maternal mortality
THE Government of South Korea and UNICEF Uganda have signed an agreement that will see the former give to the latter for taming the high maternal and new-born mortality in Karamoja and Acholi...
Latest Ebola trial vaccine
The latest in a string of candidate vaccines against the deadly Ebola virus is proven safe in an early trial....
New tool to predict heart attack/stroke risk
A new instrument will allow you to determine your risk simply by inputting your age, gender, blood pressure and cholesterol numbers....
Will the ban of food vendors help eliminate typhoid?
Yes
No
Can't Say
follow us
subscribe to our news letter